CTLA4 and neoplasm: Multiple T cell checkpoint molecules have been described, and the blockade of either of of these two inhibitory proteins, cytotoxic T-lymphocyte antigen 4 (CTLA4) and programmed cell death protein 1 (PD-1), has resulted in clinical benefit in several tumor types [3,4,5,6].